Status:

TERMINATED

Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

Lead Sponsor:

M.D. Anderson Cancer Center

Conditions:

Oropharyngeal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Standard-of-care treatment options for oropharyngeal cancer often result in long-term side effects that interfere with normal quality of life. A minimally-invasive transoral robotic surgery (TORS) app...

Detailed Description

Study Surgery: If you are found to be eligible to take part in this study, you will be scheduled for surgery. You will receive general anesthesia to make you sleep during the procedure. You will be a...

Eligibility Criteria

Inclusion

  • Patients with a previously untreated, T1 or T2, N0-N2b transorally resectable (as determined by the treating surgeon), histologically proven HPV positive, squamous cell carcinoma (SCC) of the oropharynx.
  • Eastern Cooperative Oncology Group (ECOG) PS 0-2.
  • Age \>/= 18 years.
  • Negative serum pregnancy test in females of childbearing potential.
  • Patients must sign a study-specific informed consent form prior to treatment.

Exclusion

  • Evidence of distant metastases (below the clavicle) by clinical or radiographic examination.
  • Evidence of any other primary cancers or metastases. Evidence of deep soft-tissue or bony invasion, which would preclude TMIS by clinical and/or radiographic exam.
  • Contraindications to general anesthesia.
  • Patients who have had chemotherapy or radiotherapy to the oropharynx prior to entering the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with tumors whose resection would necessitate a free-tissue transfer for reconstruction of the surgical defect.

Key Trial Info

Start Date :

September 23 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 8 2017

Estimated Enrollment :

1 Patients enrolled

Trial Details

Trial ID

NCT02225496

Start Date

September 23 2014

End Date

December 8 2017

Last Update

December 15 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030